Vasomodulatory action of clopidogrel and ticlopidine.

Clopidogrel is a thienopyridine derived antiplatelet drug that has currently undergone extensive clinical trials in the management of various arterial disorders related to platelet activation. While the proposed mechanism of its pharmacologic action is believed to be the inhibition of ADP mediated direct and indirect actions on platelet adhesion/aggregation and other activation processes, several other observed pharmacologic actions suggest that this drug may also have additional sites of action. Ticlopidine also belongs to the same class of ADP receptor inhibitor and is extensively used for prevention of ischemic disorders. In order to investigate the vasomodulatory action of clopidogrel and ticlopidine, rabbit and rat isolated tissue preparation systems were used. Clopidogrel and ticlopidine were found to produce dose dependent vasomodulatory actions in rabbit or rat treated with 30 minutes intravenous administration. The aortas harvested from both the rabbits and rats treated with clopidogrel or ticlopidine exhibited marked desensitization to the serotonin, endothelin-1, serum and platelet rich plasma/arachidonic acid mixtures. Both control rabbit aortic rings and rat aortic strips did not produce any inhibition of the serotonin induced contraction. These data suggest that clopidogrel and ticlopidine plays an important role in producing these vasomodulatory actions. Furthermore these observations indicate that both the clopidogrel and ticlopidine also modulate the vascular sites which may be contributory to the observed clinical effects.

[1]  J. Herbert,et al.  The Antiaggregating Activity of Clopidogrel Is due to a Metabolic Activation by the Hepatic Cytochrome P450-1A , 1994, Thrombosis and Haemostasis.

[2]  D. Clement.  A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .

[3]  J. Herbert,et al.  Potentiating Effect of Clopidogrel and SR 46349, a Novel 5-HT2 Antagonist, on Streptokinase-Induced Thrombolysis in the Rabbit , 1993, Thrombosis and Haemostasis.

[4]  J. Couch.  Antiplatelet therapy in the treatment of cerebrovascular disease , 1993, Clinical cardiology.

[5]  H. Fujiwara,et al.  Antithrombotic Effect of Ticlopidine on Occlusive Thrombi of Small Coronary Arteries in (NZWxBXSB)F1 Male Mice with Myocardial Infarction and Systemic Lupus Erythematosus , 1995, Journal of cardiovascular pharmacology.

[6]  M. Gent.  A Systematic Overview of Randomized Trials of Antiplatelet Agents for the Prevention of Stroke, Myocardial Infarction, and Vascular Death , 1993 .

[7]  J. Herbert,et al.  Effect of Various Antiplatelet Agents on Acute Arterial Thrombosis in the Rat , 1993, Thrombosis and Haemostasis.

[8]  J. Herbert,et al.  Effect of aspirin and clopidogrel on platelet-dependent tissue factor expression in endothelial cells. , 1994, Thrombosis research.

[9]  M. Ito,et al.  Ticlopidine: a new platelet aggregation inhibitor. , 1992, Clinical Pharmacist.

[10]  T. Matsuda,et al.  Antithrombotic effect of ticlopidine on He-Ne laser-induced thrombus formation in rat mesenteric microvessels. , 1992, Haemostasis.

[11]  K. Higo,et al.  Antithrombotic effects of KW-3635, a thromboxane A2-receptor antagonist, in guinea pigs. , 1994, Japanese journal of pharmacology.

[12]  C. Bauters,et al.  Two‐pronged antiplatelet therapy with aspirin and ticlopidine without systemic anticoagulation: an alternative therapeutic strategy after bailout stent implantation , 1995, Coronary artery disease.

[13]  J. Herbert,et al.  Aprotinin reduces clopidogrel-induced prolongation of the bleeding time in the rat. , 1993, Thrombosis research.

[14]  T. Urabe,et al.  Compliance with antiplatelet therapy in patients with ischemic cerebrovascular disease. Assessment by platelet aggregation testing. , 1994, Stroke.

[15]  H. Anderson,et al.  Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis. , 1994, The American journal of physiology.

[16]  J. May,et al.  The Antithrombotic Effects of Ticlopidine and Aspirin in a Microvascular Thrombogenic Model , 1995, Plastic and reconstructive surgery.

[17]  J. Desager.  Clinical Pharmacokinetics of Ticlopidine , 1994, Clinical pharmacokinetics.

[18]  M. Dennis.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee , 1996 .

[19]  J. Herbert,et al.  Binding of [3H]-2-methylthio ADP to rat platelets--effect of clopidogrel and ticlopidine. , 1994, The Journal of pharmacology and experimental therapeutics.

[20]  J. Fareed,et al.  Modulation of smooth muscle responses by serine proteases and related enzymes. , 1986, Seminars in Thrombosis and Hemostasis.

[21]  W. Hass,et al.  Ticlopidine, Platelets and Vascular Disease , 2011, Springer New York.

[22]  J. Herbert,et al.  Evidence for the existence of two different ADP-binding sites on rat platelets. , 1994, Thrombosis research.

[23]  M. Nakashima,et al.  Inhibitory effect of clopidogrel, vapiprost and argatroban on the middle cerebral artery thrombosis in the rat. , 1995, Japanese journal of pharmacology.

[24]  P. Flores-Runk,et al.  Ticlopidine and Antiplatelet Therapy , 1993, The Annals of pharmacotherapy.

[25]  J. Herbert,et al.  Inhibitory effect of clopidogrel on platelet adhesion and intimal proliferation after arterial injury in rabbits. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[26]  K. Yokota,et al.  Anti-thrombotic activity of KBT-3022 in experimental models of thrombosis. , 1995, Japanese journal of pharmacology.